NeuroOne Medical Technologies to Showcase Neurological Innovations at December 2025 Medical Conferences

NeuroOne Medical Technologies Corporation has announced its participation in two significant medical industry conferences scheduled for December 2025. The company, which trades on Nasdaq under the symbol NMTC, will present at both the American Epilepsy Society Annual Meeting and the CNS Drug Delivery Summit, demonstrating its ongoing commitment to neurological disorder treatment innovation. This dual-conference participation matters because it positions NeuroOne at the forefront of critical industry discussions where treatment paradigms for complex neurological conditions are evolving, potentially influencing future clinical practices and patient care standards.

The company will first participate in the American Epilepsy Society 2025 Annual Meeting in Atlanta, Georgia, from December 5th through December 9th. This gathering brings together healthcare providers, scientists, advocates, industry professionals, and other experts dedicated to improving outcomes for epilepsy patients. The conference serves as a crucial platform for sharing the latest research and technological advancements in epilepsy care. More information about the event can be found at https://www.aesnet.org/meetings_events/annual_meeting. NeuroOne's presence at this specific conference is important because epilepsy remains a challenging condition affecting millions worldwide, and new technological solutions could significantly improve diagnostic accuracy, treatment efficacy, and patient quality of life, addressing a substantial unmet medical need.

Immediately following the epilepsy conference, NeuroOne will attend the CNS Drug Delivery Summit in Boston, Massachusetts, from December 9th through 11th. This seventh annual summit will host over 100 industry experts including neuroscientists, chemists, device engineers, conjugation scientists, DMPK experts, and delivery specialists. The event focuses on collaborative efforts to address the unique challenges in delivering treatments to the brain. Conference details are available at https://www.cnsdrugdelivery.com. The significance of attending this summit lies in the critical barrier that drug delivery presents for neurological treatments; overcoming the blood-brain barrier and achieving targeted delivery could revolutionize treatment outcomes for numerous brain disorders, making NeuroOne's involvement in these discussions potentially impactful for future therapeutic developments.

NeuroOne's participation in these conferences underscores the company's strategic focus on developing comprehensive solutions for neurological conditions. The company specializes in creating minimally invasive and high-definition technologies for EEG recording, monitoring, ablation, drug delivery, and stimulation applications. These technologies target patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain resulting from failed back surgeries. The implication of this technological focus is substantial, as minimally invasive approaches could reduce patient recovery times, decrease complication rates, and make advanced neurological treatments accessible to broader patient populations, potentially transforming standard care protocols across multiple neurological specialties.

The timing of these conference appearances comes as NeuroOne continues to expand its portfolio of neurological treatment options. The company's technology platform aims to improve patient outcomes while potentially reducing procedural costs across multiple neurological conditions. Beyond its current focus areas, NeuroOne has indicated potential future applications in depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence integration. This expansion into adjacent therapeutic areas demonstrates the platform technology's versatility and suggests that successful implementation in current focus areas could lead to broader healthcare impacts, addressing some of medicine's most persistent and challenging conditions through innovative technological solutions.

Conference participation represents a critical component of NeuroOne's commercial strategy, providing opportunities to showcase technological advancements to key stakeholders in the neurological care community. These events facilitate knowledge exchange and collaboration opportunities that could accelerate the development and adoption of improved treatment modalities for patients with challenging neurological conditions. The importance of this strategic approach lies in the medical device industry's reliance on clinical adoption and expert validation; by engaging directly with leading clinicians and researchers at these premier conferences, NeuroOne can gather essential feedback, build crucial partnerships, and potentially accelerate regulatory pathways and market acceptance for its innovative technologies.